microRNA-340-5p functions downstream of cardiotrophin-1 to regulate cardiac eccentric hypertrophy and heart failure via target gene dystrophin

International Heart Journal

Volumn 56, Issue 4, 2015, Pages 454-458

  Zhou, Jian ^a   Gao, Jie ^a   Zhang, Xiaoya ^a   Liu, Yan ^a   Gu, Song ^a   Zhang, Xitao ^a   An, Xiangguang ^a   Yan, Jun ^a   Xin, Yue ^a   Su, Pixiong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; Non coding RNA

Indexed keywords

ANTAGOMIR; CARDIOTROPHIN 1; DYSTROPHIN; LENTIVIRUS VECTOR; LEUKEMIA INHIBITORY FACTOR; MICRORNA; MICRORNA 340; MICRORNA 340 5P; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTOCAVAL FISTULA; ARTICLE; CARDIAC ECCENTRIC HYPERTROPHY; ECHOCARDIOGRAPHY; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HEART CELL CULTURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEIC ACID STRUCTURE, METABOLISM AND FUNCTION; PHENOTYPE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; AORTA; ARTERIOVENOUS SHUNT; CARDIOMEGALY; CELL CULTURE; DISEASE MODEL; GENETICS; HEART VENTRICLE; HUMAN; INFERIOR CAVA VEIN; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; SURGERY;

ANIMALS; AORTA; ARTERIOVENOUS SHUNT, SURGICAL; CARDIOMEGALY; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DYSTROPHIN; HEART VENTRICLES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICE; MICRORNAS; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION; VENA CAVA, INFERIOR;

EID: 84936998888     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-386     Document Type: Article

References (30)

1. Rosca MG, Tandler B, Hoppel CL. Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2013; 55: 31-41.
2. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012; 3: 1078.
3. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-60.
4. Papageorgiou N, Tousoulis D, Androulakis E, et al. The role of microRNAs in cardiovascular disease. Curr Med Chem 2012; 19: 2605-10.
5. Orenes-Piñero E, Montoro-García S, Patel JV, Valdés M, Marín F, Lip GY. Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol 2013; 167: 1651-9.
6. Jeong MH, Lee JS, Kim do H, Park WJ, Yang DK. Identification of novel microRNAs negatively regulating cardiac hypertrophy. Biochem Biophys Res Commun 2012; 428: 191-6.
7. Han M, Yang Z, Sayed D, et al. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res 2012; 93: 64554.
8. Kelly M, Bagnall RD, Peverill RE, et al. A polymorphic miR-155 binding site in AGTR1 is associated with cardiac hypertrophy in Friedreich ataxia. J Mol Cell Cardiol 2011; 51: 848-54.
9. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-8.
10. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A 2009; 106: 12103-8.
11. Zhu X, Wang H, Liu F, et al. Identification of micro-RNA networks in end-stage heart failure because of dilated cardiomyopathy. J Cell Mol Med 2013; 17: 1173-87.
12. Ge Y, Pan S, Guan D, et al. MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Biochim Biophys Acta 2013; 1832: 1-10.
13. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 2007; 292: H3057-64.
14. Yanagawa B, Lovren F, Pan Y, et al. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J Thorac Cardiovasc Surg 2012; 144: 256-62.
15. van Mil A, Grundmann S, Goumans MJ, et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res 2012; 93: 655-65.
16. Xiong D, Lee GH, Badorff C, et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 2002; 8: 872-7.
17. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 1996; 271: 9535-45.
18. Zolk O, Ng LL, O’Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 106: 1442-6.
19. Calabrò P, Limongelli G, Riegler L, et al. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol 2009; 46: 142-8.
20. Pan J, Fukuda K, Saito M, et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1999; 84: 1127-36.
21. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 2000; 150: 1209-14.
22. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320-6.
23. Bristow MR, Long CS. Cardiotrophin-1 in heart failure. Circulation 2002; 106: 1430-2.
24. Tsutamoto T, Wada A, Maeda K, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38: 1485-90.
25. Ruiz-Hurtado G, Gómez-Hurtado N, Fernández-Velasco M, et al. Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. Cardiovasc Res 2012; 96: 81-9.
26. Celik A, Sahin S, Koc F, et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit 2012; 18: 25-31.
27. Ravassa S, Beloqui O, Varo N, et al. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens 2013; 31: 587-94.
28. Stejskal D, Ruzicka V. Cardiotrophin-1. Review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 9-19.
29. Scheuermann-Freestone M, Freestone NS, Langenickel T, Höhnel K, Dietz R, Willenbrock R. A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail 2001; 3: 535-43.
30. Jacobs PA, Hunt PA, Mayer M, Bart RD. Duchenne muscular dystrophy (DMD) in a female with an X/autosome translocation: further evidence that the DMD locus is at Xp21. Am J Hum Genet 1981; 33: 513-8.